BiotechTube

Secukinumab + Secukinumab and Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Axial Psoratic Arthritis

Conditions

Axial Psoratic Arthritis

Trial Timeline

Oct 3, 2016 → Jun 26, 2019

NCT ID
NCT02721966

About Secukinumab + Secukinumab and Placebo

Secukinumab + Secukinumab and Placebo is a phase 3 stage product being developed by Novartis for Axial Psoratic Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02721966. Target conditions include Axial Psoratic Arthritis.

What happened to similar drugs?

6 of 20 similar drugs in Axial Psoratic Arthritis were approved

Approved (6) Terminated (1) Active (14)
✅AdalimumabAbbVieApproved
✅Secukinumab 150 milligram [Cosentyx]NovartisApproved
✅Secukinumab + Placebo + SecukinumabNovartisApproved
✅etanercept + etanercept + placeboPfizerApproved
✅Tofacitinib 5 MGPfizerApproved
✅Certolizumab PegolUCBApproved
🔄Brodalumab + PlaceboKyowa KirinPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02721966Phase 3Completed

Competing Products

20 competing products in Axial Psoratic Arthritis

See all competitors
ProductCompanyStageHype Score
SUNPG1622 I dose + Placebo doseSun PharmaceuticalPhase 2
27
Brodalumab + PlaceboKyowa KirinPhase 3
40
Ixekizumab + PlaceboEli LillyPhase 3
40
Ixekizumab + PlaceboEli LillyPhase 3
40
SHR0302 + SHR0302 placeboJiangsu Hengrui MedicinePhase 3
36
SHR-1314Jiangsu Hengrui MedicinePhase 1
29
UpadacitinibAbbViePre-clinical
33
AdalimumabAbbVieApproved
35
Adalimumab + Placebo + Open-label AdalimumabAbbViePhase 3
40
adalimumab + PlaceboAbbViePhase 3
40
TreatmentMerckPre-clinical
66
GolimumabMerckPhase 3
40
Tulisokibart + PlaceboMerckPhase 2
42
Secukinumab 150 milligram [Cosentyx]NovartisApproved
39
secukinumabNovartisPre-clinical
26
Secukinumab + PlaceboNovartisPhase 3
40
Secukinumab + Placebo + SecukinumabNovartisApproved
47
Secukinumab/Adalimumab-BiosimilarNovartisPhase 3
40
Brodalumab 210 mg + PlaceboAmgenPhase 2
27
Etanercept 25mg + SulfasalazinePfizerPhase 2
31